<p>Gladstone Institutional Advisory LLC 在最近向证券交易委员会（SEC）提交的 13F 表格中表示，在第三季度将其在赛默飞世尔（Thermo Fisher Scientific Inc.，NYSE:TMO - 免费报告）的持股减少了 32.1%。该公司在此期间出售了 1,921 股后，持有 4,069 股医疗研究公司的股票。截至其最近的 SEC 文件，Gladstone Institutional Advisory LLC 在赛默飞世尔的持股价值为 1,974,000 美元。</p>
<ul>
<li>行业轮动：2026 年的两项聪明资金举措</li>
</ul>
<p>其他几家对冲基金和机构投资者也对其在该公司的持仓进行了调整。CBIZ Investment Advisory Services LLC 在第一季度将其在赛默飞世尔的持股增加了 137.5%。CBIZ Investment Advisory Services LLC 目前持有 57 股医疗研究公司的股票，价值 28,000 美元，此前在上个季度又购买了 33 股。Highline Wealth Partners LLC 在第三季度将其在赛默飞世尔的持仓增加了 126.9%。Highline Wealth Partners LLC 目前持有 59 股医疗研究公司的股票，价值 29,000 美元，此前在此期间又获得了 33 股。Anderson Financial Strategies LLC 在第一季度购买了赛默飞世尔的新头寸，价值 30,000 美元。Capital A Wealth Management LLC 在第二季度将其在赛默飞世尔的持股增加了 825.0%。Capital A Wealth Management LLC 目前持有 74 股医疗研究公司的股票，价值 30,000 美元，此前在上个季度又购买了 66 股。最后，DiNuzzo Private Wealth Inc. 在第二季度将其在赛默飞世尔的持股增加了 406.7%。DiNuzzo Private Wealth Inc. 目前持有 76 股医疗研究公司的股票，价值 31,000 美元，此前在此期间又购买了 61 股。对冲基金和其他机构投资者持有该公司 89.23% 的股票。</p>
<h2>华尔街分析师预测增长</h2>
<p>一些股票分析师最近对 TMO 股票发表了评论。Redburn Partners 在 10 月 8 日的研究报告中将赛默飞世尔的目标价设定为 580.00 美元。汇丰全球研究在 12 月 1 日的报告中将赛默飞世尔的评级从 “持有” 上调至 “强力买入”。Evercore ISI 在周一重申了 “跑赢大盘” 的评级，并对赛默飞世尔的股票发布了 650.00 美元的目标价。Cowen 在周三的研究报告中重申了对赛默飞世尔股票的 “买入” 评级。最后，Wall Street Zen 在 10 月 25 日的报告中将赛默飞世尔的评级从 “持有” 上调至 “买入”。一位股票研究分析师给予该股票 “强力买入” 评级，二十位给予 “买入” 评级，三位给予 “持有” 评级。根据 MarketBeat.com 的数据，赛默飞世尔目前的平均评级为 “适度买入”，共识目标价为 621.70 美元。</p>
<ul>
<li>机构看好这三家公司，你也应该关注吗？</li>
</ul>
<p><strong>获取我们最新的 TMO 股票分析</strong></p>
<h2>赛默飞世尔股价下跌 0.6%</h2>
<p>周四，NYSE TMO 开盘价为 616.97 美元。该公司的 50 日移动平均价格为 579.34 美元，200 日移动平均价格为 514.40 美元。赛默飞世尔的 12 个月低点为 385.46 美元，12 个月高点为 628.08 美元。该公司的债务与股本比率为 0.62，流动比率为 1.50，速动比率为 1.11。该公司的市值为 2318 亿美元，市盈率为 35.64，市盈增长比率为 4.08，贝塔值为 0.91。</p>
<ul>
<li>这三只股票通过回购传递市场信心</li>
</ul>
<p>赛默飞世尔（NYSE:TMO - 获取免费报告）最近在 10 月 22 日发布了季度财报。该医疗研究公司报告的每股收益（EPS）为 5.79 美元，超出市场共识预期的 5.50 美元，超出幅度为 0.29 美元。赛默飞世尔的净利润率为 15.02%，股本回报率为 16.97%。该公司在本季度的收入为 111.2 亿美元，而市场共识预期为 109 亿美元。在去年同期，该公司每股收益为 5.28 美元。赛默飞世尔本季度的收入同比增长 4.9%。赛默飞世尔已将其 2025 财年的指引设定为每股收益 22.600-22.860 美元。平均而言，卖方分析师预计赛默飞世尔将在当前财年发布每股收益 23.28 美元。</p>
<h2>赛默飞世尔宣布分红</h2>
<p>该公司最近还宣布了一项季度分红，将于 1 月 15 日（星期四）支付。12 月 15 日（星期一）的股东将获得每股 0.43 美元的分红。该分红的除息日为 12 月 15 日（星期一）。这代表着每年 1.72 美元的分红和 0.3% 的收益率。赛默飞世尔的派息比率为 9.94%。</p>
<p>赛默飞世尔宣布其董事会于 11 月 6 日启动了一项股票回购计划，授权公司回购 50 亿美元的流通股。该回购授权允许该医疗研究公司通过公开市场购买最多 2.4% 的股份。股票回购计划通常表明公司的管理层认为其股票被低估。</p>
<h2>内部买卖</h2>
<p>在其他新闻中，执行副总裁弗雷德里克·M·洛瑞于 12 月 2 日星期二出售了 6,912 股公司的股票。股票的平均售价为 581.94 美元，总交易额为 4,022,369.28 美元。交易完成后，这位执行副总裁直接持有公司 14,367 股股票，估值约为 8,360,731.98 美元。这笔交易代表了他们持股比例的 32.48% 的减少。该出售在向 SEC 的法律文件中披露，相关信息可通过此链接访问。此外，首席执行官马克·N·卡斯帕于 10 月 27 日星期一出售了 7,250 股公司的股票。股票的平均售价为 566.10 美元，总交易额为 4,104,225.00 美元。出售完成后，首席执行官持有公司 113,762 股股票，估值约为 64,400,668.20 美元。这笔交易代表了他们持股比例的 5.99% 的减少。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去 90 天内，内部人士已出售 149,271 股公司股票，价值 86,507,282 美元。公司内部人士持有公司股票的 0.33%。</p>
<h2>关于赛默飞世尔</h2>
<p>（免费报告）</p>
<p>赛默飞世尔 NYSE: TMO 是全球科学仪器、试剂和耗材、软件及服务的提供商，支持研究、临床和工业实验室。该公司提供分析仪器和实验室设备、生命科学试剂和试剂盒、专业诊断以及研究人员、临床医生和制造商使用的广泛耗材。其产品还包括实验室信息管理和数据分析软件，以及帮助客户高效运行复杂工作流程的服务解决方案，如仪器维护、验证和物流。</p>
<p>赛默飞通过多个业务领域运营，广泛涵盖生命科学解决方案、分析仪器、专业诊断、实验室产品和生物制药服务，包括为制药和生物技术公司提供的合同开发和制造服务。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过赛默飞世尔</li>
<li>你还认为白银是个笑话？看看接下来会发生什么。</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>崩盘前一个月</li>
<li>请勿删除，立即阅读</li>
<li>YDES 可能是 2026 年的生物技术突破</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRNTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRNTw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在赛默飞世尔吗？</h2>
<p>在考虑赛默飞世尔之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而赛默飞世尔并不在名单上。</p>
<p>虽然赛默飞世尔目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

赛默飞世尔

<p>Gladstone Institutional Advisory LLC 在第三季度减少了对赛默飞世尔（Thermo Fisher Scientific Inc.，NYSE:TMO）32.1% 的持股，目前持有 4,069 股，价值 1,974,000 美元。其他机构投资者也调整了他们的持仓。分析师为 TMO 设定的共识目标价为 621.70 美元，大多数分析师给予其 “适度买入” 的评级。该公司报告了第三季度每股收益为 5.79 美元，超出预期，营收为 111.2 亿美元，同比增长 4.9%。赛默飞世尔还宣布了季度分红</p>

<p>Gladstone Institutional Advisory LLC cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 32.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,069 shares of the medical research company's stock after selling 1,921 shares during the period. Gladstone Institutional Advisory LLC's holdings in Thermo Fisher Scientific were worth $1,974,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Gladstone Institutional Advisory LLC 在最近向证券交易委员会（SEC）提交的 13F 表格中表示，在第三季度将其在赛默飞世尔（Thermo Fisher Scientific Inc.，NYSE:TMO - 免费报告）的持股减少了 32.1%。该公司在此期间出售了 1,921 股后，持有 4,069 股医疗研究公司的股票。截至其最近的 SEC 文件，Gladstone Institutional Advisory LLC 在赛默飞世尔的持股价值为 1,974,000 美元。</p>
</div><ul>
<li>Sector Rotation: 2 Smart Money Moves for 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>行业轮动：2026 年的两项聪明资金举措</li>
</ul>
</div><p>Several other hedge funds and other institutional investors have also made changes to their positions in the business. CBIZ Investment Advisory Services LLC lifted its holdings in Thermo Fisher Scientific by 137.5% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock worth $28,000 after buying an additional 33 shares in the last quarter. Highline Wealth Partners LLC increased its position in shares of Thermo Fisher Scientific by 126.9% during the third quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company's stock worth $29,000 after acquiring an additional 33 shares during the period. Anderson Financial Strategies LLC purchased a new position in Thermo Fisher Scientific in the first quarter valued at $30,000. Capital A Wealth Management LLC grew its stake in Thermo Fisher Scientific by 825.0% during the 2nd quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company's stock worth $30,000 after purchasing an additional 66 shares in the last quarter. Finally, DiNuzzo Private Wealth Inc. increased its holdings in Thermo Fisher Scientific by 406.7% during the 2nd quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company's stock worth $31,000 after purchasing an additional 61 shares during the period. Hedge funds and other institutional investors own 89.23% of the company's stock.</p>
<div class="lb-trans"><p>其他几家对冲基金和机构投资者也对其在该公司的持仓进行了调整。CBIZ Investment Advisory Services LLC 在第一季度将其在赛默飞世尔的持股增加了 137.5%。CBIZ Investment Advisory Services LLC 目前持有 57 股医疗研究公司的股票，价值 28,000 美元，此前在上个季度又购买了 33 股。Highline Wealth Partners LLC 在第三季度将其在赛默飞世尔的持仓增加了 126.9%。Highline Wealth Partners LLC 目前持有 59 股医疗研究公司的股票，价值 29,000 美元，此前在此期间又获得了 33 股。Anderson Financial Strategies LLC 在第一季度购买了赛默飞世尔的新头寸，价值 30,000 美元。Capital A Wealth Management LLC 在第二季度将其在赛默飞世尔的持股增加了 825.0%。Capital A Wealth Management LLC 目前持有 74 股医疗研究公司的股票，价值 30,000 美元，此前在上个季度又购买了 66 股。最后，DiNuzzo Private Wealth Inc. 在第二季度将其在赛默飞世尔的持股增加了 406.7%。DiNuzzo Private Wealth Inc. 目前持有 76 股医疗研究公司的股票，价值 31,000 美元，此前在此期间又购买了 61 股。对冲基金和其他机构投资者持有该公司 89.23% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of equities analysts have recently commented on TMO shares. Redburn Partners set a $580.00 price objective on Thermo Fisher Scientific in a research report on Wednesday, October 8th. Hsbc Global Res upgraded shares of Thermo Fisher Scientific from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a report on Monday, December 1st. Evercore ISI restated an &#34;outperform&#34; rating and issued a $650.00 price objective on shares of Thermo Fisher Scientific in a report on Monday. Cowen reaffirmed a &#34;buy&#34; rating on shares of Thermo Fisher Scientific in a research report on Wednesday. Finally, Wall Street Zen raised Thermo Fisher Scientific from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Saturday, October 25th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $621.70.</p>
<div class="lb-trans"><p>一些股票分析师最近对 TMO 股票发表了评论。Redburn Partners 在 10 月 8 日的研究报告中将赛默飞世尔的目标价设定为 580.00 美元。汇丰全球研究在 12 月 1 日的报告中将赛默飞世尔的评级从 “持有” 上调至 “强力买入”。Evercore ISI 在周一重申了 “跑赢大盘” 的评级，并对赛默飞世尔的股票发布了 650.00 美元的目标价。Cowen 在周三的研究报告中重申了对赛默飞世尔股票的 “买入” 评级。最后，Wall Street Zen 在 10 月 25 日的报告中将赛默飞世尔的评级从 “持有” 上调至 “买入”。一位股票研究分析师给予该股票 “强力买入” 评级，二十位给予 “买入” 评级，三位给予 “持有” 评级。根据 MarketBeat.com 的数据，赛默飞世尔目前的平均评级为 “适度买入”，共识目标价为 621.70 美元。</p>
</div><ul>
<li>Institutions Love These 3 Companies, Should You As Well?</li>
</ul>
<div class="lb-trans"><ul>
<li>机构看好这三家公司，你也应该关注吗？</li>
</ul>
</div><p><strong>Get Our Latest Stock Analysis on TMO</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 TMO 股票分析</strong></p>
</div><h2>Thermo Fisher Scientific Trading Down 0.6%</h2>
<div class="lb-trans"><h2>赛默飞世尔股价下跌 0.6%</h2>
</div><p>NYSE TMO opened at $616.97 on Thursday. The firm's fifty day moving average price is $579.34 and its 200 day moving average price is $514.40. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $628.08. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. The company has a market capitalization of $231.80 billion, a price-to-earnings ratio of 35.64, a price-to-earnings-growth ratio of 4.08 and a beta of 0.91.</p>
<div class="lb-trans"><p>周四，NYSE TMO 开盘价为 616.97 美元。该公司的 50 日移动平均价格为 579.34 美元，200 日移动平均价格为 514.40 美元。赛默飞世尔的 12 个月低点为 385.46 美元，12 个月高点为 628.08 美元。该公司的债务与股本比率为 0.62，流动比率为 1.50，速动比率为 1.11。该公司的市值为 2318 亿美元，市盈率为 35.64，市盈增长比率为 4.08，贝塔值为 0.91。</p>
</div><ul>
<li>These 3 Stocks Are Using Buybacks to Signal Market Confidence</li>
</ul>
<div class="lb-trans"><ul>
<li>这三只股票通过回购传递市场信心</li>
</ul>
</div><p>Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The company had revenue of $11.12 billion during the quarter, compared to the consensus estimate of $10.90 billion. During the same quarter in the prior year, the firm posted $5.28 earnings per share. Thermo Fisher Scientific's revenue for the quarter was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>赛默飞世尔（NYSE:TMO - 获取免费报告）最近在 10 月 22 日发布了季度财报。该医疗研究公司报告的每股收益（EPS）为 5.79 美元，超出市场共识预期的 5.50 美元，超出幅度为 0.29 美元。赛默飞世尔的净利润率为 15.02%，股本回报率为 16.97%。该公司在本季度的收入为 111.2 亿美元，而市场共识预期为 109 亿美元。在去年同期，该公司每股收益为 5.28 美元。赛默飞世尔本季度的收入同比增长 4.9%。赛默飞世尔已将其 2025 财年的指引设定为每股收益 22.600-22.860 美元。平均而言，卖方分析师预计赛默飞世尔将在当前财年发布每股收益 23.28 美元。</p>
</div><h2>Thermo Fisher Scientific Announces Dividend</h2>
<div class="lb-trans"><h2>赛默飞世尔宣布分红</h2>
</div><p>The company also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific's payout ratio is 9.94%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度分红，将于 1 月 15 日（星期四）支付。12 月 15 日（星期一）的股东将获得每股 0.43 美元的分红。该分红的除息日为 12 月 15 日（星期一）。这代表着每年 1.72 美元的分红和 0.3% 的收益率。赛默飞世尔的派息比率为 9.94%。</p>
</div><p>Thermo Fisher Scientific declared that its board has initiated a share buyback plan on Thursday, November 6th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to reacquire up to 2.4% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company's management believes its stock is undervalued.</p>
<div class="lb-trans"><p>赛默飞世尔宣布其董事会于 11 月 6 日启动了一项股票回购计划，授权公司回购 50 亿美元的流通股。该回购授权允许该医疗研究公司通过公开市场购买最多 2.4% 的股份。股票回购计划通常表明公司的管理层认为其股票被低估。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In other news, EVP Frederick M. Lowery sold 6,912 shares of the firm's stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $581.94, for a total transaction of $4,022,369.28. Following the transaction, the executive vice president directly owned 14,367 shares in the company, valued at approximately $8,360,731.98. This trade represents a 32.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Marc N. Casper sold 7,250 shares of the company's stock in a transaction on Monday, October 27th. The shares were sold at an average price of $566.10, for a total transaction of $4,104,225.00. Following the completion of the sale, the chief executive officer owned 113,762 shares of the company's stock, valued at approximately $64,400,668.20. This trade represents a 5.99% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 149,271 shares of company stock valued at $86,507,282 in the last 90 days. Company insiders own 0.33% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，执行副总裁弗雷德里克·M·洛瑞于 12 月 2 日星期二出售了 6,912 股公司的股票。股票的平均售价为 581.94 美元，总交易额为 4,022,369.28 美元。交易完成后，这位执行副总裁直接持有公司 14,367 股股票，估值约为 8,360,731.98 美元。这笔交易代表了他们持股比例的 32.48% 的减少。该出售在向 SEC 的法律文件中披露，相关信息可通过此链接访问。此外，首席执行官马克·N·卡斯帕于 10 月 27 日星期一出售了 7,250 股公司的股票。股票的平均售价为 566.10 美元，总交易额为 4,104,225.00 美元。出售完成后，首席执行官持有公司 113,762 股股票，估值约为 64,400,668.20 美元。这笔交易代表了他们持股比例的 5.99% 的减少。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去 90 天内，内部人士已出售 149,271 股公司股票，价值 86,507,282 美元。公司内部人士持有公司股票的 0.33%。</p>
</div><h2>About Thermo Fisher Scientific</h2>
<div class="lb-trans"><h2>关于赛默飞世尔</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.</p>
<div class="lb-trans"><p>赛默飞世尔 NYSE: TMO 是全球科学仪器、试剂和耗材、软件及服务的提供商，支持研究、临床和工业实验室。该公司提供分析仪器和实验室设备、生命科学试剂和试剂盒、专业诊断以及研究人员、临床医生和制造商使用的广泛耗材。其产品还包括实验室信息管理和数据分析软件，以及帮助客户高效运行复杂工作流程的服务解决方案，如仪器维护、验证和物流。</p>
</div><p>Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.</p>
<div class="lb-trans"><p>赛默飞通过多个业务领域运营，广泛涵盖生命科学解决方案、分析仪器、专业诊断、实验室产品和生物制药服务，包括为制药和生物技术公司提供的合同开发和制造服务。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Thermo Fisher Scientific</li>
<li>You Still Think Silver’s a Joke? Watch What Happens Next.</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>A month before the crash</li>
<li>Do not delete, read immediately</li>
<li>YDES Could Be 2026's Biotech Breakthrough</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过赛默飞世尔</li>
<li>你还认为白银是个笑话？看看接下来会发生什么。</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>崩盘前一个月</li>
<li>请勿删除，立即阅读</li>
<li>YDES 可能是 2026 年的生物技术突破</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVRNTw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=TMO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Thermo Fisher Scientific Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在赛默飞世尔吗？</h2>
</div><p>Before you consider Thermo Fisher Scientific, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑赛默飞世尔之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而赛默飞世尔并不在名单上。</p>
</div><p>While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然赛默飞世尔目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Gladstone Institutional Advisory LLC 减少了其在赛默飞世尔公司的股票持有量 $TMO